FDA fast-tracks Enspryng for thyroid eye disease after promising trial results
FDA fast-tracks Enspryng for thyroid eye disease after promising trial results
FDA fast-tracks Enspryng for thyroid eye disease after promising trial results
Genentech has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for a new use of Enspryng. The drug is being considered for the treatment of thyroid eye disease (TED), a serious autoimmune condition. A decision on approval is expected by 15 October 2026. Thyroid eye disease affects around 155 people in every 100,000. It is a complex inflammatory disease that can threaten vision, cause severe discomfort, and lead to disfigurement. Enspryng, a humanised monoclonal antibody, targets interleukin-6 (IL-6), a key driver of inflammation in the body.
The FDA’s decision rests on results from two global Phase III studies, SatraGO-1 and SatraGO-2. These trials assessed the drug’s safety and effectiveness in patients with moderate to severe TED. In SatraGO-1, 49% of patients treated with Enspryng achieved a reduction in proptosis (bulging eyes), compared to 31% in the placebo group. In SatraGO-2, the figure rose to 53% for Enspryng, versus 23% for placebo.
The drug also showed improvements in secondary measures. Between 78% and 90% of patients saw reductions in their clinical activity score (CAS). Additionally, 44% to 61% experienced an improvement in double vision. No new safety concerns emerged during the trials, with Enspryng’s profile remaining consistent with its established use in neuromyelitis optica spectrum disorder. Enspryng demonstrated consistent and meaningful benefits for TED patients in both primary and secondary trial endpoints. Its safety profile remained stable, with no unexpected issues reported. The FDA’s priority review highlights the potential of this treatment for a condition with limited current options.